Alkermes ALKS Cash & Equivalents
Cash & Equivalents at other companies
Segments
By geography
See fullOther financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alkermes's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alkermes's cash & equivalents?
- Alkermes (ALKS) reported cash & equivalents of $351.55M in Q1 2026.
- How has Alkermes's cash & equivalents changed year-over-year?
- Alkermes's cash & equivalents decreased by 12.1% year-over-year, from $399.81M to $351.55M.
- What is the long-term trend for Alkermes's cash & equivalents?
- Over 5 years (2020 to 2025), Alkermes's cash & equivalents has grown at a 7.3% compound annual growth rate (CAGR), from $272.96M to $388.57M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and financial flexibility, while a significant decrease may indicate high cash burn or aggressive capital deployment.
- How does cash & equivalents compare across companies?
- Peers in the biotechnology sector typically maintain high cash balances to fund long-term clinical trials and R&D pipelines.